Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–930 of 930 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cap Clear all
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients

NCT00772148
View directory record Official record
Conditions
Liver Failure
Interventions
LCP -Tacro, Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 20, 2026, 3:41 AM EDT
Completed Not applicable Interventional Results available

Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain

NCT03940963
View directory record Official record
Conditions
Symptomatic Neuroma, Morton's Neuroma, Chronic Nerve Pain
Interventions
AxoGuard® Nerve Cap, Standard Neurectomy
Device · Procedure
Lead sponsor
Axogen Corporation
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
11
States / cities
Los Angeles, California • Saint Augustine, Florida • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 20, 2026, 3:41 AM EDT
Active, not recruiting No phase listed Observational

Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy

NCT02994693
View directory record Official record
Conditions
Barrett Esophagus, Barretts Esophagus With Dysplasia
Interventions
OFDI capsule imaging
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 3:41 AM EDT
Enrolling by invitation Not applicable Interventional

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

NCT05334784
View directory record Official record
Conditions
High-Risk Percutaneous Coronary Intervention
Interventions
Impella ECP
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 20, 2026, 3:41 AM EDT
Completed Phase 2 Interventional

Electrical Stimulation of the Internal Capsule for Intractable Obsessive-compulsive Disorder (OCD)

NCT01061983
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Medtronic Activa Deep Brain Stimulation
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 20, 2026, 3:41 AM EDT
Completed Phase 1 Interventional

Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid

NCT02274623
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Bone Neoplasms, Hypocalcemia, Hyperparathyroidism, Secondary
Interventions
CTAP101 Capsules
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Long Beach, California • Miami, Florida • Evergreen Park, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 20, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

NCT01115569
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydrocodone Bitartrate
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
50
States / cities
Phoenix, Arizona • Sierra Vista, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 20, 2026, 3:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

NCT04263142
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254 Tablet, GSK3640254 Capsule
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 20, 2026, 3:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg

NCT01163630
View directory record Official record
Conditions
Effect of Food, Pharmacokinetics
Interventions
esomeprazole/ASA Fixed Dose Combination (FDC)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Oveland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Oct 20, 2026, 3:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

NCT02723630
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lenvatinib 10 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 20, 2026, 3:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg

NCT00649636
View directory record Official record
Conditions
Healthy
Interventions
Fluoxetine Capsules 40 mg, Prozac Pulvules 40 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 20, 2026, 3:41 AM EDT
Terminated Not applicable Interventional Results available

Tolerability, Safety and Efficacy of a New Frequency of Vibrant Capsule Administration

NCT02829047
View directory record Official record
Conditions
Constipation
Interventions
Vibrating Capsule
Device
Lead sponsor
Vibrant Ltd.
Industry
Eligibility
22 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Guntersville, Alabama • Jacksonville, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 20, 2026, 3:41 AM EDT
Completed No phase listed Observational

"Evaluation of the PillCam™ESO Capsule in the Detection of Esophageal Varices

NCT00481416
View directory record Official record
Conditions
Esophageal Varices
Interventions
PillCam Eso
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Scottsdale, Arizona • Plymouth, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 20, 2026, 3:41 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)

NCT00509275
View directory record Official record
Conditions
Tinea Pedis
Interventions
W0027, Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Louisville, Kentucky • Warren, Michigan • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 20, 2026, 3:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates

NCT00577083
View directory record Official record
Conditions
Polyps
Interventions
Cap-fitted colonoscopy
Device
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 20, 2026, 3:41 AM EDT
Completed No phase listed Observational

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

NCT02921828
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
No City Provided, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 20, 2026, 3:41 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Screening Brain MRI in High School Football: Does the Guardian Cap Reduce the Risk of Traumatic Brain Injury

NCT02757053
View directory record Official record
Conditions
Brain Concussion, Brain Injuries, Diffuse Axonal Injury, Athletic Injuries, Injury, Brain, Traumatic
Interventions
Guardian Cap
Device
Lead sponsor
Mosaic Life Care
Other
Eligibility
12 Years to 20 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 20, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Results available

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT00722137
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, VELCADE 1.3 mg/m^2, Prednisone 100 mg/m^2, Vincristine 1.4 mg/m^2
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
9
States / cities
Hartford, Connecticut • Goshen, Indiana • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 20, 2026, 3:41 AM EDT